Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'" - Kim Rand; Juan Manuel Ramos-Goñi; Bülent Akmaz; Laia Solé-Feu; José-Carlos A (Adis, Springer Healthcare, 2024)